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We used human bladder cancer as a model system and the
whole-organ histologic and genetic mapping strategy to identify
clonal genetic hits associated with growth advantage, tracking the
evolution of bladder cancer from intraurothelial precursor lesions.
Six putative chromosomal regions critical for clonal expansion of
intraurothelial neoplasia and development of bladder cancer were
identified by using this approach. Focusing on one of the regions,
which includes the model tumor suppressor RB1, we performed
allelotyping of single-nucleotide polymorphic sites and identified
a 1.34-Mb segment around RB1 characterized by a loss of poly-
morphism associated with the initial expansion of in situ neoplasia.
This segment contains several positional candidate genes referred
to by us as forerunner genes that may contribute to such expan-
sion. We subsequently concentrated our efforts on the two neigh-
bor genes flanking RB1, namely ITM2B and CHC1L, as well as
P2RY5, which is located inside RB1. Here, we report that ITM2B and
P2RY5modulated cell survival and were silenced by methylation or
point mutations, respectively, and thus by functional loss may
contribute to the growth advantage of neoplasia. We also show
that homozygous inactivation of P2RY5 was antecedent to the loss
of RB1 during tumor development, and that nucleotide substitu-
tions in P2RY5 represent a cancer predisposing factor.
bladder cancer  single-nucleotide polymorphic sites  whole-organ
histologic and genetic mapping
Many common epithelial cancers, including those arising inthe bladder, begin as clonal in situ expansion of neoplastic
cells, which show no or minimal deviation from the normal
phenotype (1–4). Such lesions often form plaques involving large
areas of the affected mucosa, and their expansion precedes the
development of microscopically recognizable dysplasia or car-
cinoma in situ (4, 5). Identification of chromosomal regions
associated with the initial expansion of neoplasia is a requisite
for more specific studies of their positional candidate genes that
may drive the initial clonal expansion of neoplasia.
We have used an approach referred to as whole-organ histo-
logic and genetic mapping (WOHGM) to identify clonal hits
associated with growth advantage, tracking the evolution of
human bladder cancer from occult in situ lesions to invasive
disease on a total genomic scale (6–8). Human bladder carci-
noma was used as a model of common epithelial malignancy that
develops by progression of microscopically recognizable intrau-
rothelial preneoplastic lesions ranging from mild dysplasia to
carcinoma in situ (5). Bladder cancer was also selected because
it is close to an ideal model human tumor to study the early
events of carcinogenesis due to simple anatomy of the organ and
the ease in mapping preneoplastic conditions geographically
across the entire mucosa of cystectomy specimens (9–11).
In this paper, we begin by presenting the identification of the
six critical chromosomal regions that may contain genes driving
the development of bladder cancer. Then, we focus on one of the
regions, which contain the model tumor suppressor RB1, and by
performing high-resolution mapping with SNPs, we identified
alternative target genes subsequently referred to by us as fore-
runner (FR) genes that may contribute to the development of in
situ urothelial neoplasia. Finally, we provide evidence that their
loss of function is likely to be critical to the initial clonal
expansion of in situ neoplastic lesions.
Results and Discussion
To identify chromosomal regions that may contain genes most
relevant for the development of the initial clonal expansion of
neoplasia, we performed the genome-wide WOHGM on human
cystectomy specimens with transitional cell carcinoma (TCC)
using 787 hypervariable DNA markers (mostly microsatellites)
mapping to autosomes 1–22. By using this approach, we identi-
fied chromosomal regions characterized by clonal loss of het-
erozygosity (LOH) that had a geographic relationship to the
distribution of two major types of intraurothelial precursor
lesions [supporting information (SI) Fig. 6]. The first group
consisted of alterations associated with expansion of a dominant
clone with minimal or no phenotypic change that involved large
areas of bladder mucosa. The second group consisted of alter-
ations associated with the development of successive clones
showing a fully transformed phenotype (i.e., those related to
severe dysplasia/carcinoma in situ with subsequent progression
to invasive cancer). We identified clonal LOH with both char-
acteristics in four of the five tested bladders, with each one
showing a unique combination of changes (SI Fig. 7). However,
when constellations of putative critical losses from the individual
bladders were analyzed, it became evident that six chromosomal
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regions, mapping to 3q22-3q24, 5q22-5q31, 9q21-9q22, 10q26,
13q14, and 17p13, were involved in more than one case and could
represent six regions critical for the initial clonal expansion of
urothelial neoplasia (Fig. 1). This observation was confirmed by
testing multiple microsatellite markers mapping to the six chro-
mosomal regions on voided urine and peripheral blood from 32
patients with clinically evident bladder cancer and from 31
patients with a history of bladder tumors who were disease free
at the time of urine collection (SI Fig. 8 b–d). LOH affecting at
least one of the regions was identified in 98% of these patients,
and a similar frequency of LOH was present in patients with a
history of TCC as well as those with clinically evident disease. In
82% of the cases, synchronous involvement of two to five
chromosomal regions was present, and this confirmed that losses
in these regions were frequent in bladder cancers and thus may
contain genes critical for its development (SI Fig. 8d).
To identify prototypic genes that may drive such expansion, we
concentrated our efforts on the 13q14 region, which contains the
model tumor suppressor gene, RB1 (12). We have previously
reported that the patterns of RB1 inactivation and LOH in this
region suggest that RB1 is not providing growth advantage for in
situ urothelial neoplasia, whereas other genes in the region may
drive the initial expansion of bladder neoplasia (13). This
observation was based on low-resolution microsatellite and
limited SNP mapping, which did not permit the precise identi-
fication of the involved region and its candidate genes. To map
the positional candidate genes involved in the initial clonal
expansion of urothelial neoplasia, we performed high-resolution
whole-organ SNP-based allelotyping of the 27-megabase (Mb)
segment around RB1 (13, 14) (SI Fig. 9). When the integrated
whole-organ maps of loss of polymorphism (LOP) identified by
SNPs and maps of LOH identified by microsatellite markers
were compared with RB1 sequencing data and RB protein
expression patterns, it became evident that LOH/LOP that
affected RB1 and its f lanking regions was an early event in
bladder neoplasia (Fig. 2 and SI Fig. 10). This loss was associated
with initial clonal expansion that formed a plaque involving large
areas of bladder mucosa and was never associated with the
inactivation of the second RB1 allele. In those cases in which loss
of one RB1 allele was associated with the mutational inactivation
of the second allele, this inactivation was a later event corre-
sponding to the onset of severe dysplasia/carcinoma in situ
progressing to invasive carcinoma.
The patterns of integrated LOH and LOP identified by
microsatellite and SNP markers from five cystectomy specimens
defined the minimal region associated with clonal expansion of
in situ neoplasia, which involved a 1.34-Mb segment around
Fig. 1. Critical chromosomal regions involved in the development of bladder
cancer. For details, see SI Fig. 8. The outer circle depicts the recombination-
based map of chromosomes arranged clockwise from p to q arms. The four
innermost circles represent maps of the informative cystectomies. Green dots
designate markers with clonal LOH forming plaques involving microscopically
normal appearing urothelium (NU), LGIN, HGIN, and TCC. Red dots designate
markers with clonal LOH restricted to HGIN and TCC. Black arrows indicate six
regions critical for the development of bladder cancer.
Fig. 2. Integration of LOH and LOP patterns identified in the 13q14 region
with RB1 sequencing data and RB protein expression implicating the involve-
ment of FR genes in the intraurothelial expansion of a neoplastic clone. For
details, see SI Fig. 10. (a) Regions of LOP associated with early clonal expansion
identified by WOHGM with SNPs in five cystectomy specimens related to the
status of RB1 sequence, RB1(S), and RB protein expression revealed by immu-
nohistochemistry [RB(IH)] are illustrated. The results of RB1 sequencing and
immunohistochemical studies for RB protein expression are tabulated below
the maps of individual bladders. W, wild-type RB1. M, mutant RB1. The
mutation in map 2 involved codon 556 of exon 17 consisting of CGA3TGA and
resulting in the change of Arg to a stop codon. The presence of immunohis-
tochemically detectable RB protein is designated by . The absence of RB
protein expression is designated by, and its distribution pattern is shown in
the lower image of b. The genome sequence map with the positions of
hypervariable markers as well as known genes are designated by the bars on
the left side of map. The regions of LOP in five cystectomies (maps 1–5) are
depicted by the blue solid bars. The shadowed areas labeled delA and delB
designate the regions of LOP flanking RB1 involved in the incipient expansion
of a neoplastic clone. The shaded area labeled delRB1 designates the segment
of LOP corresponding to the position ofRB1on the sequence genome map. (b)
The distribution of clonal LOP involving RB1 and the same regions shown in a
for map 5 (upper image) is depicted. The lower image shows the distribution
of the segment with LOP in map 2 depicted in a. (c) Region of clonal LOP
associated with growth advantage of in situneoplasia identified by SNP-based
mapping. The histologic map code is as follows: NU, normal urothelium; MD,
mild dysplasia; MdD, moderate dysplasia; SD, severe dysplasia; CIS, carcinoma
in situ; and TCC. For the purpose of statistical analysis, intraurothelial precur-
sor conditions were classified into two groups: LGIN (mild to moderate dys-
plasia) and HGIN (severe dysplasia and carcinoma in situ). The immunohisto-
chemical patterns of RB protein expression in representative mucosal samples
of map 2 and map 5 are shown in SI Fig. 10.
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RB1.¶¶ Because this region was defined by WOHGM of only five
cystectomies, we further investigated the frequency of its in-
volvement on 84 paired samples of bladder tumors and periph-
eral bloodDNAby allelotyping of 92 SNPsmapping to a 3.16-Mb
segment around RB1 (Fig. 3). The position of the segment with
the most frequent LOP identified by this approach overlapped
with the position of the region associated with clonal expansion
initially found by WOHGM. (For details, see SI Text.) These
data further supported the hypothesis that genes located near the
model tumor suppressor, RB1, subsequently referred to by us as
FR genes, may significantly contribute to the development of
bladder cancer. By analyzing the predicted functions of their
encoded proteins, we decided to concentrate our initial efforts
on the two nearest neighbor genes flanking RB1, namely ITM2B,
which encodes a mitochondrial membrane protein with a Bcl-2
homology 3 (BH3) domain (15), CHC1L (RCBTB2), which
encodes a guanine nucleotide exchange factor protein for the
ras-related GTPase (16), and P2RY5 located within intron 17 of
RB1, which encodes a G protein-coupled receptor (17).
To investigate the involvement of these candidate FR genes in
bladder carcinogenesis, we initially analyzed their sequence and
expression in 12 bladder cancer cell lines and 14 paired samples
of adjacent urothelium and TCCs. The initial sequencing of
bladder cancer cell lines as well as paired samples of adjacent
urothelium and TCCs did not identify mutations within FR
genes. However, by sequencing DNA from tumors and surface
urothelium of the five resected bladders used for WOHGM as
well as paired peripheral blood DNA, we found a germ-line
deletion of G at codon 296 of the predicted P2RY5 protein (Fig.
4a); the resulting frameshift producing a stop signal at codon
302. In addition, this germ-line mutation was associated with
LOP involving a 1.27-Mb segment in the surface urothelium of
bladder mucosa (Fig. 4 b–d and SI Fig. 11). Consequently, this
loss homozygously inactivated P2RY5 in the urothelium (Fig. 4c),
whereas the remaining alleles of ITM2B, RB1, and CHC1L were
wild type. The homozygous inactivation of P2RY5 was associated
with expansion of an in situ neoplastic clone involving large areas
of bladder mucosa and the subsequent development of multi-
focal TCC. Evidence was thus provided that P2RY5 rather than
RB1 was a target for mutations within the 1.27-Mb segment in
the 13q14 region and was likely involved in the initial expansion
of the in situ neoplastic clone.
We subsequently found that the FR genes were down-
regulated in bladder cancer cell lines with inactivatedRB1 as well
as in those cell lines with wild-type RB1 (SI Fig. 12a). Typically,
more than one candidate FR gene was down-regulated, and the
reduction of expression was often 4-fold (75%). The FR
genes were often down-regulated in both superficial and invasive
TCCs and in corresponding samples of adjacent surface urothe-
lium, again suggesting their involvement in early in situ phases of
bladder neoplasia (SI Fig. 12b). To rule out the possibility of
nonspecific down-regulation of the candidate FR genes in the
¶¶LOP by SNP mapping was identified in all five cystectomy specimens, including the
specimen in which WOHGM mapping with microsatellites did not reveal LOH involving
13q14 region.
Fig. 3. Map of LOP within a 3.16-Mb segment around RB1. (a) Allelic losses
were tested on 84 paired samples of bladder tumors and peripheral blood by
using SNP multiplex technology. Predicted sizes of LOP are depicted as blue
bars, and a continuous red line shows their frequency. The genomic map
above the diagram shows positions of individual genes (solid black bars) and
tested SNPs (thin black downward bars). (Inset) The analysis of LOP and
inactivation of RB1 documented by either immunohistochemical analysis or
DNA sequencing is shown. LGPTCC, low-grade (grades 1 and 2) superficial
(Ta–T1a) papillary TCC; HGPTCC, high-grade (grade 3) nonpapillary invasive
(T1b and higher) TCC. (b) The allelic losses are related to histologic grade, RB
protein expression, RB1 mutation, methylation of ITM2B, and nucleotide
substitutions of P2RY5 summarized in a diagram on the right. Details of RB1
sequencing are provided in SI Table 1. L, low grade (grades 1–2); H, high grade
(grade 3); solid blue dots indicate the absence of RB protein expression,
mutation of RB1, methylation of ITM2B, and nucleotide substitutions in
P2RY5. Details of the analyses are provided in SI Text.
Fig. 4. Inactivation of P2RY5 is associated with expansion of in situ neopla-
sia. For details, see SI Fig. 11. (a Upper) A wild-type sequence of P2RY5. (a
Lower) A deletion of G at codon 296 after subcloning from paired peripheral
blood (PB) DNA corresponding to the cystectomy shown in d. (b) A 1.27-Mb
segment of LOP (blue bar) identified by mapping with SNPs. (c Top) A
wild-type sequence from control DNA. (c Middle and Bottom) A G–A poly-
morphism at codon 296 in the PB DNA resulting from deletion of a G residue
(Middle) and a loss of wild-type allele in bladder mucosa (Bottom) revealed by
pyrosequencing. NA, wild-type allele; MA, mutant allele. (d) Inactivation of
P2RY5 by germ-line point mutation and loss of 1.27-Mb segment as it relates
to precursor lesions and TCC in a cystectomy map (same case as shown in a–c).
The black line depicts the area of LOP involving the 1.27-Mb segment; the blue
line delineates the area with P2RY5 showing the deletion at codon 296.
TCC1–3 designate separate foci of carcinoma. The code for the histologic map
is shown in Fig. 2.
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urothelium, the expression pattern of 29 genes around RB1 was
analyzed. These studies were performed on the same 12 bladder
cancer cell lines and showed that the candidate FR genes were
the most significantly and frequently down-regulated genes
within the distance of 3 Mb around RB1 (data not shown).
Because the 5 regions of ITM2B and CHC1L have typical
CpG islands, we further investigated whether methylation of
their putative promoter regions was a mechanism responsible for
silencing these genes (SI Fig. 13). Hypermethylation of the
ITM2B promoter was identified in 6 of 12 bladder cancer cell
lines and, in each instance, was associated with2-fold (50%)
reduction in gene expression (SI Fig. 12a). Expression of ITM2B
could be restored by treatment with the DNA methylation
inhibitor 5-aza-2-deoxycytidine, confirming that methylation
was involved in silencing of this gene. The analysis of 14 paired
samples of adjacent urothelium and TCC confirmed these
observations and documented that methylation of ITM2B could
be detected in 64% of tumor samples, which was also present in
the adjacent urothelium (SI Fig. 12b). No abnormal pattern of
methylation of CHC1L was identified.
To address how frequently the candidate FR genes are
involved in bladder carcinogenesis, we performed methylation-
specific PCR and sequencing analyses of ITM2B and P2RY5 on
an additional 195 TCCs and an equal number of controls
matched for age, sex, and ethnicity. In addition, paired nontumor
DNA from the same patient in 131 of the TCCs was also
sequenced. Methylation of ITM2B followed the trend identified
in bladder cancer cell lines or paired adjacent urothelium and
tumor samples being detected in 40% of TCC. It was equally
frequent in low-grade (grade 1–2) superficial (Ta–T1a) as in
high-grade (grade 3) invasive (T1b and higher) TCCs. Missense
point mutations of P2RY5 were found in 7% of TCCs and, of
particular importance, some of these were documented as
germ-line alterations (Fig. 5a and SI Table 2). The mutations of
P2RY5 (somatic and germ-line) identified in bladder tumor
samples and paired nontumor DNA from the same patient were
not present in unaffected control samples or in the human
genome SNP databases.
Although missense mutations in P2RY5 were fairly rare, we
also detected three polymorphic sites in P2RY5, namely 1386
T-C, 1602 A-C, and 1722 G-T. A 1722 G-T polymorphism
resulting in the substitution of tryptophan for cysteine at position
307 was of potential importance because it was detected in
several bladder tumors and nontumor DNA from the same
patient. In addition, molecular models of P2RY5 protein devel-
oped by using its homology to rhodopsin suggest that this
substitution involving the cytoplasmic domain of the protein may
affect its interaction with the G protein complex and compro-
mise its biological activity (18–23) (Fig. 5b). In fact, the loss of
apoptotic activity for the 1722 T variant allele was documented
by in vitro transfection assays (see below). Therefore, we ex-
tracted DNA from laser microdissected surface bladder urothe-
lium with in situ neoplasia adjacent to invasive TCC from a
patient with 1722 G-T polymorphism. By using allele-specific
pyrosequencing, we showed that loss of a wild-type 1722 G
P2RY5 allele with retention of the variant 1722 T P2RY5 allele
occurred in in situ phase of bladder neoplasia and preceded the
loss of RB protein expression (Fig. 5 c and d).
To further investigate the role of a 1722 G-T polymorphism
of P2RY5 in the development of bladder cancer, we conducted
a case-control study on peripheral blood DNA from 790
patients with bladder cancer and 712 age- and sex-matched
controls. The heterozygous 1722 G-T P2RY5 genotype was
identified in 2.78% of bladder cancer patients and 2.81% of
controls. We did not identify any individuals with a homozy-
gous 1722 T-T genotype. In addition, the presence of 1722 G-T
genotype was not associated with an overall higher risk for
bladder cancer (adjusted odds ratio, 1.07; 95% confidence
interval, 0.57–2.03). However, it appeared that smoking mod-
ulates the effect of this polymorphism and all 1722 G-T carriers
who were smokers developed bladder cancer (odds ratio not
calculable). This strongly suggests that exposure to tobacco
smoking-related carcinogens in the presence of a 1722 T
P2RY5 allele synergistically increases the risk for bladder
cancer. Details concerning the frequency of LOP, RB1, and FR
Fig. 5. Nucleotide substitutions of P2RY5 in bladder cancers. (a) Summary of
sequence analysis of P2RY5. The positions of nucleotide substitutions are
shown on the full-length mRNA. For details, see SI Table 2. (b) A model of
inactive P2RY5 containing seven-transmembrane (H1–H7) and one cytoplas-
mic (H8) helix structures showing the position of polymorphism in codon 307
located within the cytoplasmic domain of the protein (Left) that may affect its
interaction with the G trimeric protein complex (Right). (c) A G-T polymor-
phism at codon 307 in the PB DNA resulting in substitution of cysteine for
tryptophan identified by pyrosequencing (same case as shown in d). (d)
Sequential inactivation of P2RY5 and RB1 in the development of bladder
cancer from in situ neoplasia. (Upper) Low-power view of invasive bladder
cancer and adjacent LGIN and HGIN. (Lower Left) Microdissected DNA corre-
sponding to LGIN shows loss of wild-typeP2RY5allele and retention of normal
RB expression pattern. (Lower Center) Microdissected DNA corresponding to
HGIN shows similar loss of wild-type P2RY5 allele and additional loss of RB
protein expression. (Lower Right) Same loss of wild-type P2RY5 allele and loss
of RB protein expression is seen in invasive TCC. Arrows indicate retention of
RB protein expression in endothelial cells adjacent to tumor. (Scale bars,
50 m.)
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genes inactivation in various pathogenetic subsets of TCC are
provided in SI Text.
Collectively, our data strongly suggest that loss of FR gene
function promotes early clonal expansion, presumably by directly
regulating cell proliferation and/or cell death. Indeed, analysis of
the ITM2B sequence identified a putative BH3 domain, a
sequence motif that mediates the proapoptotic functions of an
important family of cell-death regulators (24). To test this
hypothesis, we transiently transfected ITM2B and P2RY5 expres-
sion constructs into the ITM2B- and P2RY5-deficient UC6
bladder cancer cell line, which showed 4-fold down-regulation
of both genes but has wild-type RB1 (SI Fig. 14). Because human
urothelial and bladder cancer cells express alternatively spliced
long (L) and short (S) variants of ITM2B (data not shown), the
experiments were performed with the constructs containing
ITM2BL and ITM2BS inserts. Because ITM2BS was previously
shown to be the apoptotically active form of ITM2B protein and
this activity was attributed to an unmasked BH3 domain (15), we
performed additional experiments with constructs containing
inactivating mutations within its BH3 domain. These included
constructs with: (i) substitutions involving two conserved amino
acids at positions 35 and 40; (ii) substitutions of eight amino acids
at positions 34–41; and (iii) a deletion of the entire predicted
BH3 domain involving amino acids at positions 31–45 (SI Fig.
14a). To verify that nucleotide substitutions of P2RY5 identified
in clinical samples alter its function, we developed additional
constructs containing mutant P2RY5 inserts. These included
constructs with: (i) a deletion of G at codon 296 causing a
frameshift with downstream stop signal at codon 302 identified
as a homozygous mutation in one of the cystectomies used for
WOHGM (see Fig. 4) and (ii) a 1722 T variant allele resulting
in the amino acid substitution at position 307 involved in the 1722
G-T polymorphism (see Fig. 5).
Ectopically driven expression of a wild-type ITM2BS, as well
as of a wild-type P2RY5, reduced rates of proliferation in
recipient cells (SI Fig. 14 c and d). These effects were associated
with induction of apoptosis as measured by specific proteolytic
processing of procaspase-3 and DNA fragmentation (SI Fig. 14
b, e, and f). In contrast, mutant ITM2BS constructs lacking a
functional BH3 domain had no effect on caspase activation or
DNA fragmentation (SI Fig. 14 b, e, and f). Transfections with
a wild-type ITM2BL showed no evidence of apoptotic activity.
Similarly, transfections with constructs containing mutant
P2RY5 inserts showed that nucleotide substitutions identified in
cancer samples including a substitution associated with 1722 G-T
polymorphism abolished its apoptotic effect. Transfections with
a wild-type CHC1L construct showed no effect on cell prolif-
eration or survival (data not shown).
Our findings support the existence of distinct genes, referred
to by us as FR genes, mapping contiguously toRB1. Similar genes
may also be present in the remaining five chromosomal regions
we have identified. The FR genes are related to tumor suppres-
sors in the sense that they appear to contribute to tumorigenesis
by loss of function, but their inactivation precedes the functional
loss of tumor suppressors such as RB1 during tumor develop-
ment. In fact, we have documented sequential homozygous
inactivation of a candidate FR gene P2RY5 and RB1 in the
development of bladder cancer. Although the mutational inac-
tivation of this candidate FR gene is rare, it provides strong
evidence supporting its involvement in early phases of bladder
neoplasia. In addition, a 1722 G-T polymorphism in P2RY5 was
associated with an increased risk for bladder cancer development
when combined with the exposure to tobacco smoking. More-
over, epigenetic silencing of another candidate FR gene, ITM2B,
by methylation appears to be a frequent occurrence responsible
for silencing of this gene in bladder carcinogenesis. In this
scenario, the FR genes provide the initial growth advantage for
a neoplastic clone, whereas subsequent inactivation of tumor
suppressors is a transforming event associated with the devel-
opment of a successor clone with features of severe dysplasia/
carcinoma in situ. Because in some cases allelic loss associated
with clonal expansion of in situ neoplasia involved not only FR
genes but also RB1, the possibility that RB1 haploinsufficiency
might play a role in the development of premalignant lesions in
these cases cannot be excluded. However, survivors with hered-
itary retinoblastoma carrying only one wild-type copy of RB1 in
their somatic cells develop normally, and they do not show
hyperproliferative changes in the urinary tract or in any other
normal tissue including the retina (25). In addition, otherwise
normal human cells carrying only one copy of the wild-type RB1
gene do not show increased growth rates or transformed phe-
notype in vitro compared with the cells carrying two copies of the
wild-type RB1 gene (26). These data indicate that RB1 haplo-
insufficiency is unlikely to provide a significant growth advan-
tage either in vivo or in vitro. It is uncertain at this time whether
the FR genes provide growth advantage in the state of haplo-
insufficiency or they contribute to tumor development after their
homozygotic inactivation. The overall pattern of LOH/LOP
identified by our mapping studies suggests that multiple FR
genes from several chromosomal regions are involved in the
development of neoplasia in vivo. The FR genes not only provide
a new paradigm for cancer development but may also represent
early detection and risk markers as well as targets for therapeutic
and preventive interventions.
Materials and Methods
Details of Materials and Methods are described in SI Text.
Mapping Strategy.WOHGM with microsatellites and SNP mark-
ers was performed on cystectomies from five patients with
high-grade (grade 3) invasive TCC according to previously
published protocols (6–8, 13, 14). In brief, testing was performed
on 234 DNA samples corresponding to areas with the following:
microscopically normal appearing urothelium (NU; n  53),
low-grade intraurothelial neoplasia (LGIN; n  82), high-grade
intraurothelial neoplasia (HGIN; n  50), and invasive TCC
(n  49). Initially, all 787 markers were tested on paired DNA
samples from TCC and nontumor DNA. LOH was identified in
196 markers that were subsequently tested on all mucosal
samples of five cystectomies. The frequencies of LOH in the six
critical chromosomal regions associated with clonal expansion of
in situ bladder neoplasia identified by WOHGM were addition-
ally tested on paired voided urine and peripheral blood samples
of 63 patients with bladder cancer. Then, we focused on one of
the regions and performed high-resolution WOHGM by using
661 SNPs mapping within a 27-Mb segment around RB1. Ini-
tially, all 661 SNPs were tested on normal genomic DNA. Then,
those SNPs that exhibited polymorphism were tested on repre-
sentative DNA samples corresponding to invasive TCC of the
same individual. Finally, those SNPs that showed LOP were
tested on all mucosal samples of the same cystectomy.
For the 13q14 region, the results of WOHGMwere confirmed
by allelotyping of 92 SNPs mapped to a 3.16-Mb segment around
RB1. Testing was performed on 84 paired samples of bladder
tumor and peripheral blood DNA using SNP multiplex (SNPlex)
technology according to previously published protocol (27).
Expression, Sequencing, and Methylation Assays. We analyzed the
expression, methylation, and sequences of FR genes in five
cystectomies used forWOHGM, 12 bladder cancer cell lines, and
14 paired samples of adjacent urothelium and TCCs. Because
these analyses showed that the two FR genes, ITM2B and P2RY5,
were altered by hypermethylation and mutations, respectively,
we analyzed their methylation and sequence in 195 TCCs.
Sequencing of P2RY5 was also performed on peripheral blood
DNA from 195 age-, gender-, and race-matched, unaffected
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controls. For 131 TCCs, paired nontumor DNA samples were
also sequenced.
The epidemiologic analysis of 1722 G-T polymorphism involv-
ing P2RY5 was performed on peripheral blood samples from 790
patients with bladder cancer and 712 age- and sex-matched
controls. The allelotyping was performed by using TaqMan SNP
assay, and the data were analyzed by using STATA software as
described previously (28).
Immunohistochemical staining for RB protein was performed
according to previously published protocol (29).
Vector-Driven in Vitro Transfection Assays. We cloned ITM2BL,
ITM2BS, P2RY5, and CHC1L cDNA into the mammalian ex-
pression vectors: pEGFP-c1 and pflag-c1 (Clontech, San Jose,
CA). ITM2B and P2RY5mutants were generated by site-directed
mutagenesis using QuikChange Site-Directed Mutagenesis kit
(Stratagene, La Jolla, CA). For transient transfection, 2  106
cells were suspended in 100 l of Nucleofector solution con-
taining 2–5 g of vector DNA, and electroporated by using
Nucleofector apparatus II (Amaxa Biosystems, Gaithersburg,
MD). The apoptotic activity was tested by fluorescent flow-
cytometric DNA fragmentation and by proteolytic processing of
procaspase-3 assays as described previously (30).
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